Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) EPS (Weighted Average and Diluted) (2024 - 2025)

Historic EPS (Weighted Average and Diluted) for Kairos Pharma (KAPA) over the last 2 years, with Q2 2025 value amounting to -$0.08.

  • Kairos Pharma's EPS (Weighted Average and Diluted) fell 30000.0% to -$0.08 in Q2 2025 from the same period last year, while for Jun 2025 it was -$0.34, marking a year-over-year change of. This contributed to the annual value of -$0.27 for FY2024, which is 5606.57% down from last year.
  • Kairos Pharma's EPS (Weighted Average and Diluted) amounted to -$0.08 in Q2 2025, which was down 30000.0% from -$0.08 recorded in Q1 2025.
  • Kairos Pharma's 5-year EPS (Weighted Average and Diluted) high stood at -$0.02 for Q2 2024, and its period low was -$0.14 during Q4 2024.